ITMR - Itamar Medical sees Q3 as high as $11M above consensus

Itamar Medical (ITMR) reports preliminary results for Q3 and revenue guidance for FY 2020.Total revenue for Q3 is expected to be $10.7M to $11M, an increase of 32% to 36% compared to Q3 2019 and above consensus of $9.49M.Q3 U.S. WatchPAT revenue of $8.6M to $8.9M. On April 13, 2020, Itamar Medical withdrew its FY 2020 revenue guidance due to COVID-19 uncertainties. The Company is reinstating its full year revenue guidance to a range of $39.5M to $40.5M, growth of approx. 26% to 29% Y/Y, higher than the average analyst estimate of $38.38M. The Company expects to issue full third quarter 2020 results in mid-November.Wall Street Rating is Very Bullish with price target of $26.76 whereas Quant Rating is Neutral.

For further details see:

Itamar Medical sees Q3 as high as $11M, above consensus